SynthesisBMJ open2019
Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis.
Synthesis in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis.The Lancet. Child & adolescent health · 2022Pooled it
- Coronary Artery Calcification and Plaque Characteristics in People Living With HIV: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2021Pooled it
- Effect of Omega-3 Polyunsaturated Fatty Acids Treatment on Lipid Pattern of HIV Patients: A Meta-Analysis of Randomized Clinical Trials.Marine drugs · 2020Pooled it
- Epidemiology of Antiretroviral Therapy Related Adverse Drug Reactions and its Predictors Among Patients with Human Immunodeficiency Virus/AIDS in Ethiopia: A Systematic Review and Meta-analysis.Journal of the International Association of Providers of AIDS CarePooled it
- Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial.Arteriosclerosis, thrombosis, and vascular biology · 2026Trial
- A prospective cohort study of the SEARCH integrated HIV/hypertension community health worker-led intervention in rural Kenya and Uganda.Journal of the International AIDS Society · 2025Trial
- Major adverse cardiovascular events, morbidity, and mortality, among people living with and without HIV in two northern Uganda hospitals.BMC infectious diseases · 2026Article
- Antiviral Drugs in HIV and Cardiovascular Disease: Mechanistic Insights and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Rate of nicotine metabolism on risk of myocardial infarction among people with HIV who smoke cigarettes.PloS one · 2026Article
- Article
- Hidden risks of first-line regimen switching in antiretroviral therapy-treated patients.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2025Article
- Statin use in people with HIV.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Review
- Thrombotic and cardiovascular events in HIV infection (Review).Biomedical reports · 2025Review
- Burden of Chronic Health Conditions Among People With HIV and Common Non-AIDS-Defining Cancers.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Article
- Association of prior tuberculosis with altered cardiometabolic profiles of people with HIV: A comparative cross-sectional study in Uganda.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Cardiovascular Outcomes After Acute Coronary Syndrome in Persons Living with HIV: A Scoping Review.Current cardiology reports · 2025Article
- Immune Dysregulation in Ischemic Heart Disease Among Individuals with Human Immunodeficiency Virus.Heart failure clinics · 2025Review
- Non-Communicable Diseases in Patients with Human Immunodeficiency Virus and Their Risk Factors.Infection & chemotherapy · 2025Article
- No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors.The Journal of antimicrobial chemotherapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCardiovascular disease (CVD) is one of the leading non-AIDS-defining causes of death among HIV-positive (HIV+) individuals. However, the evidence surrounding specific components of CVD risk remains inconclusive. We conducted a systematic review and meta-analysis to synthesise the available evidence and establish the risk of myocardial infarction (MI) among HIV+ compared with uninfected individuals. We also examined MI risk within subgroups of HIV+ individuals according to exposure to combination antiretroviral therapy (ART), ART class/regimen, CD4 cell count and plasma viral load (pVL) levels.
designSystematic review and meta-analysis. DATA SOURCES: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews until 18 July 2018. Furthermore, we scanned recent HIV conference abstracts (CROI, IAS/AIDS) and bibliographies of relevant articles. ELIGIBILITY CRITERIA: Original studies published after December 1999 and reporting comparative data relating to the rate of MI among HIV+ individuals were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers working in duplicate, independently extracted data. Data were pooled using random-effects meta-analysis and reported as relative risk (RR) with 95% CI.
resultsThirty-two of the 8130 identified records were included in the review. The pooled RR suggests that HIV+ individuals have a greater risk of MI compared with uninfected individuals (RR: 1.73; 95% CI 1.44 to 2.08). Depending on risk stratification, there was moderate variation according to ART uptake (RR, ART-treated=1.80; 95% CI 1.17 to 2.77; ART-untreated HIV+ individuals: 1.25; 95% CI 0.93 to 1.67, both relative to uninfected individuals). We found low CD4 count, high pVL and certain ART characteristics including cumulative ART exposure, any/cumulative use of protease inhibitors as a class, and exposure to specific ART drugs (eg, abacavir) to be importantly associated with a greater MI risk.
conclusionsOur results indicate that HIV infection, low CD4, high pVL, cumulative ART use in general including certain exposure to specific ART class/regimen are associated with increased risk of MI. The association with cumulative ART may be an index of the duration of HIV infection with its attendant inflammation, and not entirely the effect of cumulative exposure to ART per se. PROSPERO REGISTRATION NUMBER: CRD42014012977.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.